NCT01192984已完成2 期
Phase II Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 38
- 试验地点
- 15
- 主要终点
- Antitumor effect (best overall response)
研究概览
简要总结
The purpose of this study is to evaluate the efficacy of KW-0761 intravenously administered eight times at one-week intervals in patients with CCR4-positive peripheral T/NK-cell lymphoma. The primary objective is to assess the antitumor effect in terms of best overall response, while the secondary objectives are to assess the antitumor effect in terms of best response by disease lesion, to assess the progression-free survival and to assess the overall survival. The safety and pharmacokinetic profiles of KW-0761 will be also evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with hematologically or pathohistologically diagnosed peripheral T/NK-cell lymphoma
- •Subjects who have been positive for CCR4
- •Subjects who received one or more chemotherapy regimens
- •Subjects who relapse after achieving complete response, uncertain complete response or partial response by the last chemotherapy
- •Subjects who have an interval of 4 weeks or more between the last day of the prior therapy and the scheduled day of the first KW-0761 treatment
- •Subjects with nodal lesions, extranodal lesions and/or cutaneous lesions
- •Subjects who have a performance status of 0 to 2
- •Subjects who are negative for HBs antigen and reported as "not detected" for HBV-DNA
- •Subjects who are negative for anti-HCV antibody
- •Subjects who have normal function of the major organs
- •Subjects who have given written voluntary informed consent to participate in the study
排除标准
- •Subjects who underwent transplant therapy such as hematopoietic stem-cell transplantation (Subjects who underwent autologous hematopoietic stem-cell transplantation following chemotherapy will not be excluded)
- •Subjects who are known carriers of HIV
- •Subjects who have active multiple cancer
- •Subjects who have a history of allergic reactions to therapeutic antibodies
- •Subjects requiring continuous systemic treatment with steroid
- •Subjects who require emergency radiotherapy for treating the symptoms caused by bulky masses at enrollment or who may require such radiotherapy after the start of the study
- •Subjects who are pregnant, lactating or of childbearing potential, or who are planning to have children
结局指标
主要结局
Antitumor effect (best overall response)
次要结局
- Antitumor effect (best response by disease lesion), progression-free survival and overall survival
- Adverse events and anti-KW-0761 antibody levels
- Plasma KW-0761 concentrations and pharmacokinetic parameters
研究者
研究点 (15)
Loading locations...
相似试验
未知
2 期
Phase II study of KW-0761JPRN-jRCT2080220744Kyowa Hakko Kirin Co., Ltd.25
未知
2 期
Phase II study of KW-0761 in subjects with CCR4-positive peripheral T/NK-cell lymphomaJPRN-jRCT2080221219Kyowa Hakko Kirin Co., Ltd.
已完成
2 期
Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphomaAdult T-cell Leukemia-lymphomaNCT00920790Kyowa Kirin Co., Ltd.28
终止
3 期
A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM)HTLV-1 Associated MyelopathyNCT03191526Kyowa Kirin Co., Ltd.66
终止
2 期
A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast CancerBreast NeoplasmsNeoplasm MetastasisNCT00102895Pfizer25